ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors Suffering Losses to Find Counsel Ahead of Important Deadline in Securities Class Action – AKBA

New York, New York–(Newsfile Corp. – April 10, 2022) – WHY: Rosen Law Firm, a global investor rights law firm, reminds buyers of Akebia Therapeutics, Inc. AKBA between June 28, 2018 and September 2, 2020 inclusive (the “Class Period”), the significant May 13, 2022 lead applicant deadline.

SO WHAT: If you purchased Akebia securities during the Class Period, you may be entitled to compensation without payment of fees or out-of-pocket costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Akebia class action, go to https://rosenlegal.com/submit-form/?case_id=4028 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for class action information. A class action lawsuit has already been filed. If you wish to act as lead plaintiff, you must move the Court no later than May 13, 2022. A lead plaintiff is a representative party acting on behalf of other class members to direct litigation.

WHY THE ROSEN LAW: We encourage investors to select qualified attorneys with proven track records in leadership roles. Often, companies issuing reviews do not have comparable experience, resources, or significant peer recognition. Many of these firms do not actually handle securities class action lawsuits, but are merely middlemen who refer clients or partner with law firms that actually litigate the cases. Be wise in choosing lawyers. Rosen Law Firm represents investors worldwide, focusing its practice on securities class action and shareholder derivative litigation. Rosen Law Firm has reached the largest securities class action settlement against a Chinese company. Rosen Law Firm was ranked #1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has ranked in the top 4 every year since 2013 and has recovered hundreds of million dollars for investors. In 2019 alone, the company secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, the defendants throughout the class action period made false and/or misleading statements and/or failed to disclose that: (1) vadadustat was not as safe to treat NDD- CKD suffering from anemia that the defendants had represented him; (2) as a result, the defendants overstated the clinical prospects of the PRO2TECT program; (3) as a result, the defendants also overstated Vadadustat’s overall business and regulatory prospects; and (4) therefore, Akebia’s public statements were materially false and misleading at all relevant times. When the real details entered the market, the lawsuit claims investors suffered damages.

To join the Akebia class action, go to https://rosenlegal.com/submit-form/?case_id=4028 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for class action information.

No class has been certified. Until a class is certified, you are not represented by an attorney unless you retain one. You can choose the lawyer of your choice. You can also remain an absent party member and do nothing at this point. An investor’s ability to participate in any potential future recovery does not depend on their status as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Lawyer advertisement. Previous results do not guarantee a similar result.

——————————-

Contact information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, Pennsylvania
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/119817